entertainment -WSS

entertainment

author：fashion 2025-09-28 11:20:52 - browse：3824

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： House transparency, PBM reform bill gains bipartisan support

WSS

Snackable artificial intelligence, expert AI, and the pharma industry

Medical school prerequisites are outdated

After decades in use, heart stents finally beat placebo

Ohio still needs to do more to protect the right to abortion

Ethical issues complicate the benefits of medical crowdfunding

First transplant of an entire human eye performed

leisure time

entertainment

focus

Psychedelics group wrestles with new pharma identity

NIH nominee Bertagnolli will get October confirmation hearing

Heart attack and stroke risk calculators need revising

Snackable artificial intelligence, expert AI, and the pharma industry

Medical leaders decry Supreme Court decision on affirmative action

What is STAT's opinion section for?

How one medical school became remarkably diverse

Snackable artificial intelligence, expert AI, and the pharma industry

Guidelines to prevent youth baseball injuries need more muscle

Stem cell treatment guidelines are released by FDA

leisure time

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

The (many) problems with a new study criticizing cancer screening

ALS advocates say criticism of new drugs misses bigger picture

What health policies could hitch a ride on a spending bill?

Healthy food access boosts outcomes in two studies

Weight loss drugs should be covered by insurers, AMA says

hotspot

focus

hotspot

hotspot